期刊
CANCER CELL INTERNATIONAL
卷 22, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12935-022-02658-z
关键词
EpCAM; HGF/MET; NF-kappa B; Wnt; MAP/PI3K/mTOR
类别
Tumors use various pathways to evade the immune system, which can be bypassed through alternative routes. Key molecules such as MET, HGF, and EpCAM, which are overexpressed in some cancers, share intracellular signaling pathways. Simultaneous targeting of these molecules can help inhibit substitute pathways that tumors use to evade the immune system and develop resistance to therapy.
As an intelligent disease, tumors apply several pathways to evade the immune system. It can use alternative routes to bypass intracellular signaling pathways, such as nuclear factor-kappa B (NF-kappa B), Wnt, and mitogen-activated protein (MAP)/phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR). Therefore, these mechanisms lead to therapeutic resistance in cancer. Also, these pathways play important roles in the proliferation, survival, migration, and invasion of cells. In most cancers, these signaling pathways are overactivated, caused by mutation, overexpression, etc. Since numerous molecules share these signaling pathways, the identification of key molecules is crucial to achieve favorable consequences in cancer therapy. One of the key molecules is the mesenchymal-epithelial transition factor (MET; c-Met) and its ligand hepatocyte growth factor (HGF). Another molecule is the epithelial cell adhesion molecule (EpCAM), which its binding is hemophilic. Although both of them are involved in many physiologic processes (especially in embryonic stages), in some cancers, they are overexpressed on epithelial cells. Since they share intracellular pathways, targeting them simultaneously may inhibit substitute pathways that tumor uses to evade the immune system and resistant to therapeutic agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据